Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) will present research data on its dermatologic gene expression profile (GEP) tests at the 2025 Winter Clinical Dermatology Conference in Hawaii. The company will showcase three posters focusing on different tests:

1. DecisionDx-Melanoma: Research on i31-SLNB's ability to identify melanoma patients with low risk of SLN positivity

2. DecisionDx-SCC: Study on using 40-GEP test to identify high-risk immunosuppressed patients with cutaneous squamous cell carcinoma

3. MyPath Melanoma: Research on enabling access to prognostic GEP testing for invasive melanoma

The posters will be displayed in the Queen's Ballroom 5-6 throughout the conference, with additional information available at Castle's exhibit hall booth.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of gene expression profile (GEP) tests at the 2025 Winter Clinical Dermatology Conference - Hawaii, taking place Feb. 14-19 in Waikoloa Village, Hawaii.

“As long-standing supporters of the Winter Clinical Dermatology Conferences, we aim to facilitate meaningful conversations on advancing patient care,” said Rebecca Critchley-Thorne, Ph.D., vice president of research and development at Castle Biosciences. “The data we are sharing reinforces our commitment to improving the care of patients with skin cancers through innovative tests that can guide more informed disease management decisions.”

Details regarding Castle’s posters are included below. Posters will be available for viewing in the Queen's Ballroom 5-6 for the duration of the conference.

DecisionDx®-Melanoma
Poster title: The i31-SLNB identifies patients with cutaneous melanoma who have less than 5% risk of SLN positivity while the CP-GEP does not
Lead Author: J. Michael Guenther, M.D., St. Elizabeth Physicians General & Vascular Surgery, Edgewood, Kentucky

DecisionDx®-SCC
Poster title: Use of the 40-gene expression profile (40-GEP) test to identify immunosuppressed patients with Brigham and Women’s Hospital (BWH) T1-T2a cutaneous squamous cell carcinoma (cSCC) at higher risk of metastasis: Implications for adjuvant radiation
Lead Author: Karina Brito, BS, Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio

MyPath® Melanoma
Poster title: Enabling access to prognostic gene expression profile (GEP) testing for invasive melanoma by leveraging RNA-based testing in the diagnostic workflow
Lead Author: Brooke H Russell, Ph.D., Castle Biosciences, Inc., Friendswood, Texas

Additional information regarding these posters and Castle’s participation at Winter Clinical can be found at the company’s booth, located in the exhibit hall on the Grand Promenade.

About DecisionDx-Melanoma

DecisionDx-Melanoma is a gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient’s individual risk of sentinel lymph node positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma’s clinical value is supported by more than 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test’s results. Through Sept. 30, 2024, DecisionDx-Melanoma has been ordered approximately 183,000 times for patients diagnosed with cutaneous melanoma. Learn more at www.CastleBiosciences.com.

About DecisionDx-SCC

DecisionDx-SCC is a 40-gene expression profile test that uses an individual patient’s tumor biology to stratify risk of metastasis in patients with cutaneous squamous cell carcinoma who have one or more NCCN high-risk factors. The test result, in which patients are stratified into a Class 1 (low), Class 2A (higher) or Class 2B (highest) risk category, predicts individual metastatic risk to inform risk-appropriate management and guide decision-making regarding the use of adjuvant radiation therapy. Peer-reviewed publications have demonstrated that DecisionDx-SCC is an independent predictor of metastatic risk and that the test can significantly improve risk-stratification when used with traditional staging systems and clinicopathologic risk factors to guide risk-aligned management and treatment decisions. Learn more at www.CastleBiosciences.com.

About MyPath Melanoma

MyPath Melanoma is Castle’s gene expression profile test designed to provide an accurate, objective result to aid dermatopathologists and dermatologists in characterizing difficult-to-diagnose melanocytic lesions. Of the approximately two million suspicious pigmented lesions biopsied annually in the U.S., Castle estimates that approximately 300,000 of those cannot be confidently classified as either benign or malignant through traditional histopathology methods. For these cases, the treatment plan can also be uncertain. Obtaining accurate, objective ancillary testing can mean the difference between a path of overtreatment or the risk of undertreatment. Interpreted in the context of other clinical, laboratory and histopathologic information, MyPath Melanoma is designed to reduce uncertainty and provide confidence for dermatopathologists and help dermatologists deliver more informed patient management plans. Learn more at www.CastleBiosciences.com.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning: Castle’s ability to facilitate meaningful conversations on advancing patient care; and the ability of Castle’s test portfolio to improve the care of patients with skin cancers and AD. The words “believe,” “can,” “could,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250212186377/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

FAQ

What data will Castle Biosciences (CSTL) present at the 2025 Winter Clinical Dermatology Conference?

Castle Biosciences will present data on three GEP tests: DecisionDx-Melanoma (i31-SLNB study), DecisionDx-SCC (40-GEP test study), and MyPath Melanoma (prognostic GEP testing research).

When and where will Castle Biosciences (CSTL) present its dermatologic test data in 2025?

Castle Biosciences will present its data at the Winter Clinical Dermatology Conference taking place February 14-19, 2025, in Waikoloa Village, Hawaii.

What is the focus of Castle Biosciences' (CSTL) DecisionDx-SCC poster presentation?

The DecisionDx-SCC poster focuses on using the 40-GEP test to identify immunosuppressed patients with BWH T1-T2a cutaneous squamous cell carcinoma who are at higher risk of metastasis.

What is the main finding of Castle Biosciences' (CSTL) i31-SLNB melanoma research?

The research shows that i31-SLNB can identify melanoma patients who have less than 5% risk of SLN positivity, while the CP-GEP does not.